Coronaviruses roadmap:
Vaccines
Research roadmap for coronavirus vaccine development
Download 202402 Draft Coronavirus Vaccine research roadmap Final
---
config:
theme: default
defaultRenderer: 'elk'
themeVariables:
lineColor: "red"
---
flowchart LR
33145["
2
Naturally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine4
Inactivated vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine7
Vectored vaccines- ASafety
- BPlatform route
- CPlatform delivery
- DEfficacy in challenge model
1
Vaccine9
Adjuvant4
Inactivated vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
8
Attenuated organisms3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
8
Attenuated organisms9
Adjuvant10
Expression system9
Adjuvant11
Vector7
Vectored vaccines- ASafety
- BPlatform route
- CPlatform delivery
- DEfficacy in challenge model
12
Identity of protective antigens9
Adjuvant12
Identity of protective antigens10
Expression system12
Identity of protective antigens11
Vector13
Identity of virulence factors8
Attenuated organisms13
Identity of virulence factors12
Identity of protective antigens14
Identity of immunomodulators8
Attenuated organisms14
Identity of immunomodulators12
Identity of protective antigens15
Host responses to natural infection8
Attenuated organisms15
Host responses to natural infection12
Identity of protective antigens16
Identity of mechanisms of protection"] --> 33190["12
Identity of protective antigens17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
15
Host responses to natural infection17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
14
Identity of immunomodulators17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
16
Identity of mechanisms of protection"] 33203["17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
13
Identity of virulence factors18
Challenge models17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
18
Challenge models16
Identity of mechanisms of protection"] linkStyle default stroke-width:1px,stroke:#3bcaf2Lead Summary | Challenges and gap analysis | |
---|---|---|
1 | Vaccine | Vaccine |
2D | Efficacy in challenge model | |
2C | Delivery platform | |
2B | Delivery route | |
2A | Safety | |
2 | Naturally attenuated candidates | Naturally attenuated candidates |
3D | Efficacy in challenge model | |
3C | Delivery platform | |
3B | Delivery route | |
3A | Safety | |
3 | Rationally attenuated candidates | Rationally attenuated candidates |
4D | Efficacy in challenge model | |
4C | Delivery platform | |
4B | Delivery route | |
4A | Safety | |
4 | Inactivated vaccines | Inactivated vaccines |
5D | Efficacy in challenge model | |
5C | Delivery platform | |
5B | Delivery route | |
5A | Safety | |
5 | DNA/RNA vaccines | DNA/RNA vaccines |
6D | Efficacy in challenge model | |
6C | Delivery platform | |
6B | Delivery route | |
6A | Safety | |
6 | Subunit vaccines | Subunit vaccines |
7D | Efficacy in challenge model | |
7C | Platform delivery | |
7B | Platform route | |
7A | Safety | |
7 | Vectored vaccines | Vectored vaccines |
9 | Adjuvant | Adjuvant |
8 | Attenuated organisms | Attenuated organisms |
10 | Expression system | Expression system |
11 | Vector | Vector |
12 | Identity of protective antigens | Identity of protective antigens |
13 | Identity of virulence factors | Identity of virulence factors |
14 | Identity of immunomodulators | Identity of immunomodulators |
15 | Host responses to natural infection | Host responses to natural infection |
16B | Cell-mediated immunity | Cell-mediated immunity |
16A | Antibody response | Antibody response |
16 | Identity of mechanisms of protection | Identity of mechanisms of protection |
17C | Persistence/ clearance | |
17B | Replication | |
17A | Entry | |
17 | Host-pathogen interactions | Host-pathogen interactions |
18 | Challenge models | Challenge models |